Inventor

LI ZHENG JANE

US10 patents

⚠️ This page may combine multiple inventors who share the name “LI ZHENG JANE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

3M INNOVATIVE PROPERTIES CO

2 patents

US6245776B1Jun 12, 2001

Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

3M INNOVATIVE PROPERTIES CO456 citations98

US6486168B1Nov 26, 2002

Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

3M INNOVATIVE PROPERTIES CO217 citations97

WARNER LAMBERT CO

2 patents

US6605729B1Aug 12, 2003

Crystalline forms of [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

WARNER LAMBERT CO104 citations94

US7144915B2Dec 5, 2006

Crystalline forms of [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

WARNER LAMBERT CO9 citations70

PFIZER

2 patents

US6949652B2Sep 27, 2005

Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine

PFIZER0 citations48

US6683106B2Jan 27, 2004

N-(indole-2-carbonyl)-b-alaninamide crystal forms

PFIZER0 citations48

RAQUALIA PHARMA INC

1 patent

US7960407B2Jun 14, 2011

Crystal forms of an imidazole derivative

RAQUALIA PHARMA INC15 citations78

QILU REGOR THERAPEUTICS INC

1 patent

US12516041B2Jan 6, 2026

Crystal forms of GLP-1R agonists and uses thereof

QILU REGOR THERAPEUTICS INC0 citations58

ARTHROSI THERAPEUTICS INC

1 patent

US12145917B2Nov 19, 2024

Crystalline forms of a compound for treating or preventing gout or hyperuricemia

ARTHROSI THERAPEUTICS INC1 citations57

YANG ZHENG

1 patent

US11236081B2Feb 1, 2022

Crystalline salts of corydalmine

YANG ZHENG0 citations45

LI ZHENG JANE

3M INNOVATIVE PROPERTIES CO

Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

WARNER LAMBERT CO

Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

PFIZER

Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine

N-(indole-2-carbonyl)-b-alaninamide crystal forms

RAQUALIA PHARMA INC

Crystal forms of an imidazole derivative

QILU REGOR THERAPEUTICS INC

Crystal forms of GLP-1R agonists and uses thereof

ARTHROSI THERAPEUTICS INC

Crystalline forms of a compound for treating or preventing gout or hyperuricemia

YANG ZHENG

Crystalline salts of corydalmine

Crystalline forms of [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

Crystalline forms of [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)